Publications by authors named "T S Van der Werf"

Article Synopsis
  • Clarithromycin extended-release (CLA-ER) was tested alongside rifampicin (RIF) for treating Mycobacterium ulcerans in a WHO drug trial, but RIF can lower CLA serum levels due to its effect on metabolism.
  • The study involved 30 participants who provided dried blood samples over ten hours, with findings showing a non-significant decrease in CLA levels and a slight increase in systemic exposure compared to previous standard dosages.
  • Ultimately, CLA co-administration didn't impact RIF levels or effectiveness, leading to unclear benefits of CLA-ER over immediate release formulations.
View Article and Find Full Text PDF

Background: Indicators of extensive disease-acid fast bacilli (AFB) smear positivity and lung cavitation-have been inconsistently associated with clinical rifampin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) outcomes. We evaluated the association of these indicators with end-of-treatment outcomes.

Methods: We did an individual participant data meta-analysis of people treated for RR/MDR-TB with longer regimens with documented AFB smear and chest radiography findings.

View Article and Find Full Text PDF

Observational real-world studies on therapeutic drug monitoring (TDM) in relation to pharmacokinetic (PK) target values are lacking. This study aims to describe the PK of rifampicin (RIF) and isoniazid (INH) in a real-world setting of patients with drug-susceptible TB in relation to frequently used threshold values. A total of 116 patients with TB using standard doses of RIF and INH and who had TDM as part of clinical care were included.

View Article and Find Full Text PDF

Background: Voriconazole is an antifungal drug used for the treatment of invasive fungal infections. Due to highly variable drug exposure, therapeutic drug monitoring (TDM) has been recommended. TDM may be helpful to predict exposure accurately, but covariates, such as severe inflammation, that influence the metabolism of voriconazole have not been included in the population pharmacokinetic (popPK) models suitable for routine TDM.

View Article and Find Full Text PDF

Gastrointestinal mucositis could potentially compromise drug absorption due to functional loss of mucosa and other pathophysiological changes in the gastrointestinal microenvironment. Little is known about this effect on commonly used anti-infectives. This study aimed to explore the association between different stages of gastrointestinal mucositis, drug exposure, and gut microbiota.

View Article and Find Full Text PDF